Jump to content
Sclero Forums
janey

Antitransforming growth factor (Anti-TGF) -[beta] therapy in fibrosis: recent progress and implications for systemic sclerosis

Recommended Posts

Antitransforming growth factor (Anti-TGF) -[beta] therapy in fibrosis: recent progress and implications for systemic sclerosis.

 

Anti-TGF-[beta] therapies promise to have a major impact in systemic sclerosis. Significant concerns regarding efficacy and safety need to be addresed. The identification of optimal candidates for therapy, and of biomarkers of safety and efficacy, are critical challenges ahead. J.Varga. Current Opinion in Rheumatology. 20(6):720-728, November 2008. (Also see: Causes of Scleroderma: Proteins)

 

This item was posted in the ISN Newsroom. Check the Newsroom every day for the latest scleroderma medical and support information.


Janey Willis

ISN Support Specialist

(Retired) ISN Assistant Webmaster

(Retired) ISN News Director

(Retired) ISN Technical Writer for Training Manuals

International Scleroderma Network (ISN)

Share this post


Link to post
Share on other sites

Create an account or sign in to comment

You need to be a member in order to leave a comment

Create an account

Sign up for a new account in our community. It's easy!

Register a new account

Sign in

Already have an account? Sign in here.

Sign In Now

×